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Abstract
Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), speciﬁc inhibitors of lymphocyte
proliferation, are commonly used as adjuvant therapy with calcineurin inhibitor agents after kidney transplantation.
After administration, MMF and EC-MPS are hydrolyzed to mycophenolic acid (MPA), the active form of the drug, which
must be monitored due to its narrow therapeutic window, drugedrug interactions, and large intra-and inter-individual
pharmacokinetic variability despite a ﬁxed dose. Monitoring plasma MPA level is recommended to maintain the drug
within the therapeutic window, optimize its efﬁcacy, and minimize side effects. This study aims to develop a method for
quantifying MPA and its major metabolites (mycophenolic acid glucuronide [MPAG]) using on-line solid phase
extraction (SPE) coupled with an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
in kidney transplant patients. The linearity of MPA and MPAG were 0.3e13.6 mg/mL and 2.6e232.9 mg/mL, respectively
(r2 > 0.999). The relative error of accuracy was <15%. The within-run and between-run imprecision was <5.8%. No
carryover, ion suppression, or ion enhancement were observed. This method was used to analysis of 351 plasma samples
from renal transplant patients after MMF or EC-MPS using this method showed large pharmacokinetic variability between patients. Analysis of the same samples by immunoassay showed a large positive bias compared with our validated UPLC-MS/MS method, averaging 15.1%. These results suggest that this UPLC-MS/MS method is more effective
than immunoassay for quantitation of MPA and its metabolites in clinical samples.
Keywords: MPA, Mycophenolic acid, Renal transplant, UPLC-MS/MS

1. Introduction

C

o-administration of an anti-proliferative
immunosuppressive drug and calcineurin inhibitors (tacrolimus or cyclosporine A) is the recommended treatment for patients after kidney
transplantation [1]. Mycophenolate mofetil (MMF)
and enteric-coated mycophenolate sodium (ECMPS) are both anti-proliferative immunosuppressant drugs approved by the Food and Drug
Administration (FDA) in 1995 and 2004, respectively
[2]. These drugs inhibit T and B lymphocyte proliferation. MMF and EC-MPS are prodrugs, with MMF
rapidly hydrolyzed into the active drug mycophenolic acid (MPA) after administration. In the intestine EC-MPS also is converted to active MPA.
MPA is an inhibitor of inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme in

the de novo synthesis of guanosine nucleotides.
MPA is metabolized by uridine diphosphate glucuronosyltransferase (UTG) to phenolic mycophenolic acid glucuronide (MPAG) in the liver, kidney,
and intestine and excreted in urine. The inactive
metabolite MPAG can be converted back to MPA by
b-glucuronidase during enterohepatic recirculation,
leading to a second plasma concentration peak that
can increase its toxicity. MPA is further metabolized
into two minor metabolites, acyl glucuronide
(AcMPAG) and phenolic glucoside of MPA [3]. The
elimination half-life of MPA average 18 h, MPAG
and AcMPAG are the metabolites of MPA. Studies
of MPA pharmacokinetics has shown that exposure
correlated poorly with the dose of the drug, and
many patients on standard ﬁxed dosing have subtherapeutic concentration of MPA. MPA exhibits
signiﬁcant intra-and inter-patient variation in plasma
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concentration, undergoes drugedrug interactions,
and has a narrow therapeutic window. It has therefore been suggested that monitoring plasma concentrations of MPA is useful to overcome the
variable, especially in patients after kidney transplantation [4,5]. Assays for monitoring MPA include
immunoassays [6,7], high-performance liquid chromatography with ultraviolet detection (HPLC-UV)
[8], and LC-MS/MS [9e13]. The immunoassays
approved by the FDA in 2001 are fast and easy to
carry out but can over-estimate MPA concentrations
due to nonspeciﬁc cross-reactions between antibodies and MPAG or AcMPAG [8,12]. HPLC-UV and
LC-MS/MS are more speciﬁc than immunoassays
but are still not popular because the devices needed
are highly technical and expensive. On-line SPE
combines sample preparation with chromatography,
providing cleaner samples and allowing for batch
processing. The combination of on-line SPE with
UPLC-MS/MS may provide rapid and easy analysis
for use in the clinical laboratory. This study aims to
develop and validated a simple method for clinical
laboratory measurement of MPA, MPAG, and
AcMPAG using on-line solid phase extraction (SPE)
coupled with UPLC-MS/MS. Method veriﬁcation
was conducted according to Clinical Laboratory
Improvement Amendments (CLIA) guidelines.

2. Materials and methods
2.1. Reagents and chemicals
LC-MS grade methanol was purchased from J.T
Baker (Phillipsburg, NJ, USA). Formic acid and
ammonium formate were from SigmaeAldrich (St.
Louis, MO, US). Water was prepared in-house using a
Millipore Milli-Q Advantage A10 puriﬁcation system
(Darmstadt, Germany). Liquid MPA and MPAG were
purchased from Cerilliant corporation (Round Rock,
Texas, USA). MPA-d3, MPAG-d3 and AcMPAG-d3
were from Toronto Research Chemicals (Toronto,
Canada). The structure of MAP, MPAG and AcMPAG
are shown in Fig. 1. The Chromsystems 6 PLUS1
multilevel calibrator mycophenolic acid/glucuronide
in plasma/serum calibration kit (Munich, Germany)
was used to evaluate accuracy. For immunoassays, the
mycophenolic acid Flex reagent cartridge, calibrators,
and controls were all purchased from Siemens
Healthcare Diagnostics (Frimley, UK).

Fig. 1. Structure of MPA (A), MPAG (B), and AcMPAG (C).

Gung Medical Foundation Institutional Review
Board (IRB) Protocol# 103-6727 B.
2.3. Calibrators and controls
Stock solutions of MPA (1 mg/mL) and MPAG
(1 mg/mL) were prepared in acetonitrile and stored
at 70  C. Using these stock solutions, a calibration
curve was made using pooled drug-free plasma at
concentrations of 0.0, 0.5, 1.0, 2.0, 5.0, 7.5, 10.0 mg/mL
MPA and 0.0, 10.0, 20.0, 40.0, 100.0, 150.0, 200.0 mg/
mL MPAG. Calibration curves were established by
plotting the peak area ratios of the analytes to stable
isotope labeled versus the analyte concentrations
with 1/X weighted linear regression analysis [14]
Controls contained MPA at 2.0 and 5.0 mg/mL and
MPAG at 40.0 mg/mL and 120.0 mg/mL.
2.4. Internals standards and precipitation reagents
Stock internal standard solutions of MPA-d3
(1 mg/mL), MPAG-d3 (1 mg/mL) and AcMPAG-d3
(1 mg/mL) were prepared in methanol and stored at
70  C. The protein precipitation reagent was 100%
methanol and contained MPA-d3, MPAG-d3, and
AcMPAG-d3 at 50 ng/mL, 1,000 ng/mL, and 100 ng/
mL, respectively.

2.2. Plasma samples

2.5. Sample preparation

A total of 105 renal transplant patients were
enrolled from March 2015 to January 2017, and 351
plasma samples were collected under the Chang

Calibrators and controls were prepared in drugfree plasma to compensate the matrix effect and
treated in the same way as patient samples. A 10-mL

aliquot of calibrator, control, or sample was transferred into a 1.5 mL centrifuge tube containing
500 mL of protein precipitation reagent. Each tube
was vortexed and then centrifuged at 12,000 rpm for
15 min. To 1 mL of water was added 100 mL supernatant, and the solution was directly injected into
UPLC-MS/MS.
2.6. UPLC-MS/MS instrument and condition
We used the Waters Acquity Ultra Performance
Liquid Chromatography connected to the Waters
Xevo TQ-S mass spectrometry (Manchester, UK) for
quantitation and MassLynx software for data
acquisition. The Waters Direct Connect HP Xbridge
TM C18 (2.1  30 mm; 10 mm) (Wexford, Ireland)
was used for on-line SPE, and the Waters ACQUITY
UPLC BEH C18 (2.1  50 mm; 1.7 mm) (Wexford,
Ireland) was used for analytical separation. The online SPE and column were maintained at a temperature of 65  C. Mobile phase A contained 5 mM
ammonium formate and 0.03% formic acid, and
mobile phase B contained methanol. The ﬂow rate
of the on-line SPE was set at 1.0 mL/min. The
gradient program was 25% B for 1 min, followed by
an increase to 95% for 2 min. The ﬂow rate of the
analytical column was set at 0.5 mL/min. The
gradient program was 40% B for 1 min, followed by
an increase to 95% for 1.6 min. The injection volume
was 5 mL, and the total run time was 6 min. The
mass spectrometry operated with multiple reaction
monitoring (MRM) and positive electrospray ionization. For all compounds, the optimized mass parameters were as follows: capillary voltage, 0.6 kV;
desolvation temperature, 400  C; desolvation gas
ﬂow, 800 L/h; cone gas ﬂow, 150 L/h; and source
temperature, 120  C. The MRM transitions, cone
voltages, collision energies, and dwell time used for
the analysis of MPA and its metabolites are presented in Table 1.
2.7. Method veriﬁcation
2.7.1. Linearity
Plasma was spiked with MPA or MPAG at 11
concentrations (MPA: 0.1, 1.4, 2.7, 4.1, 5.4, 6.7, 8.0, 9.3,

10.6, 12.0, 13.3 mg/mL; MPAG: 5.3, 28.3, 51.4, 74.4, 95.7,
120.5, 143.6, 166.6, 189.7, 212.7, 235.7 mg/mL). The
linearity of the assay was determined for each series
in duplicate (two consecutive injections of the same
concentration), with calculation of the coefﬁcient of
determination (R2) and bias. A calibration kit from
Chromsystems (Grafelﬁng, Germany) was used to
evaluate the accuracy of the measurements (MPA:
0.9, 1.6, 3.2, 3.8, 6.6, 9.2 mg/mL; MPAG: 16.2, 35.1, 70.1,
88.0, 157.0, 222.0 mg/mL), and bias should be <15%.
2.7.2. Imprecision
The within-run and between-run imprecision was
determined by analyzing low and high concentrations
20 times a day (within-run imprecision) and duplicating (two consecutive injections of the same concentration) on 10 different days (between-run
imprecision). The imprecision data are presented as
the standard deviation (SD) and coefﬁcient of variation
(CV%).
2.7.3. Lower limit of quantitation (LLOQ)
Decreasing concentration samples for 8 replicates
were analyzed on 5 different days. At the lowest
concentration, the CV, accuracy, and S/N ratio were
<20%, <20%, and >10, respectively.
2.7.4. Carryover
Plasma was spiked with high and low concentrations of MPA (High: MPA, 12.1 mg/mL; MPAG,
234.7 mg/mL) (Low: MPA, 2.0 mg/mL; MPAG,
40.0 mg/mL). The carryover was analyzed and
determined in the following order: L1, L2, L3, H1,
H2, L4, H3, H4, L5, L6, L7, L8, H5, H6, L9, H7, H8,
L10, H8, H9, L11. The inﬂuence of low to high concentration was calculated.
2.7.5. Ion suppression
The post-column infusion method was used [15].
A 100-ng/mL mixture of standards (MPA, MPAG,
and AcMPAG) along with 10 different drugfree plasma samples were infused into the MS detector via the T-valve. Chromatography data were
compared with blank solvent, and the ion suppression and enhancement in the peak regions were
evaluated.

Table 1. UPLC-MS/MS MRM transitions, dwell time, and cone and collision voltages used for analyzing MPA and its metabolites.
Analyte name

Quantiﬁer

MPA
MPA-d3
AcMPAG
AcMPAG-d3
MPAG
MPAG-d3

321.18
324.14
519.18
522.18
519.18
522.18

/
/
/
/
/
/

207.04
210.11
343.05
346.05
343.05
346.05

Qualiﬁer

Collision
energy (eV)

Dwell
time (s)

Cone
(V)

321.18 / 275.11

24/14
22
20/32
32
18/30
18

0.003
0.003
0.1
0.1
0.05
0.05

8
2
8
8
22
22

519.18 / 228.99
519.18 / 228.99
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2.7.6. Interference
The effects of hemolysis, triglycerides, and icteric
on the concentrations of MPA and MPAG were
evaluated.
2.8. Immunoassay
The mycophenolic acid assay was performed
using a Dimension EXL analyzer obtained from
Siemens Healthcare Diagnostics (Frimley, UK). The
functional sensitivity is claimed to be 0.2 mg/mL in
the package insert, but the assay LOQ is veriﬁed to
be 0.55 mg/mL in our laboratory.
2.9. Method comparison
PassingeBablock regression analysis was used to
assess the correlation between the two methods,
and a BlandeAltman plot was used to evaluate the
difference between the two methods. The data were
statistically analyzed using Excel.

3.2. Method veriﬁcation
The linear ranges of MPA and MPAG were
0.1e13.6 mg/mL and 0.8e232.9 mg/mL, respectively,
and the coefﬁcient of determination (R2) was >0.999
(Fig. 1 in Supplementary data). Data regarding the accuracy of the assay are shown in Table 2. The bias of
MPA and MPAG were <15% compared to commercial
standards. The LLOQ was 0.25 mg/mL for MPA and
2.61 mg/mL for MPAG. The quantitative range was
0.3e13.6 mg/mL for MPA and 2.6e232.9 mg/mL for
MPAG. The method showed good precision and the
within-run and between-run for MPA and MPAG
were <5.8% (Table 3). No interference was observed
with hemoglobin at 300 mg/dL, triglycerides at
1.119 mg/dL, or bilirubin at 6.25 mg/dL. The carryover
test showed that low concentration might not be
affected by MPA concentration at 12.1 mg/mL or MPAG
concentration at 234.7 mg/mL (Table 1 in Supplementary data). Ion suppression was evaluated by postcolumn infusion, and no ion suppression or enhancement was shown in the peak region (Fig. 3).

3. Results
3.1. UPLC-MS/MS method

3.3. Comparison between immunoassay and
UPLC-MS/MS results

The UPLC-MS/MS method used to quantify
MPA, MPAG, and AcMPAG together is shown in
Fig. 2. The sample preparation time was less than
30 min, and the total run time for UPLC-MS/MS
was 6 min. The shapes of the MPA and MPAG
peaks on the chromatogram were sharp. MPAG was
the ﬁrst eluting analyte, AcMPAG was the second,
and MPA was the last (Fig. 2).

We compared the immunoassay and UPLC-MS/
MS method by analyzing 351 samples. PassingBablock regression analysis showed good linearity
between the two methods (Fig. 4A), with a Pearson
coefﬁcient of r ¼ 0.99 for MPA. BlandeAltman
regression analysis showed a signiﬁcant positive
bias of 15.1% (95% CI, 15.3e50.0%) (Fig. 4B).

A-MPAG Quantifier

B

A

B-MPA Quantifier

A-MPAG Qualifier

B

A

B-MPA Qualifier

A-MPAG-d3

A

C

B

B-MPA-d3
C-AcMPAG-d3

Fig. 2. Chromatography of patient samples with added MPA (3.5 mg/mL) and MPAG (113.7 mg/mL). AcMPAG-d3 was added to monitor the presence/
absence of the unstable metabolite AcMPAG.

Table 2. Accuracy of determining concentrations of the analyzed compounds.
n ¼ 12

MPA

level
level
level
level
level
level

1
2
3
4
5
6

n ¼ 12

Mean
(mg/mL)

Target value
(mg/mL)

Bias (%)

1.1
1.7
3.4
4.1
7.3
10.3

0.9
1.6
3.2
3.8
6.6
9.2

13.8
8.0
6.5
8.5
11.1
11.4

3.4. Assay method applied to patients treated with
MPA
We used the veriﬁed method to analyze 351
plasma samples of patients who were administrated
0e1,500 mg/mL MMF or EC-MPS. We observed
plasma concentrations of <0.3e17.8 mg/mL MPA
and <2.6e192.8 mg/mL MPAG. In 120 samples cotreated with MPA and tacrolimus, the plasma MPA
concentration range was <0.3e13.2 mg/mL; in 36
samples co-treated with MPA and cyclosporine A,
the plasma MPA concentration range was <0.3e15.8
mg/mL. No correlation was observed between dose
and concentration, and the results showed large
inter- and intra-individual variation.

4. Discussion
The data show that we successfully established a
robust assay that uses on-line SPE coupled with
UPLC-MS/MS to quantify MPA, MPAG, and
monitor the presence of AcMPAG together in one
sample. According to a previous study, AcMPAG is
a metabolite of MPA, and the structure of AcMPAG
is unstable [16]. The AcMPAG metabolite concentration was relatively low and less stable than that of
MPA and MPAG. MPA is primarily glucuronidated
to the major inactive MPA phenolic glucuronide
metabolite (MPAG) and the minor active MPA acyl
glucuronide metabolite (AcMPAG) by uridine
diphosphate glucuronosyl transferase (UGT) at the
phenolic hydroxyl group and the acyl group,
respectively. AcMPAG seems to be associated with
the gastrointestinal toxicity of MPA. However, it is

MPAG

Mean
(mg/mL)

Target value
(mg/mL)

Bias (%)

14.9
30.7
61.7
77.4
133.8
192.8

16.2
35.1
70.1
88.0
157.0
222.0

8.0
12.4
11.9
12.0
14.8
13.0

controversial whether AcMPAG monitoring is
helpful for predicting efﬁcacy and toxicity in MPA
therapy, because only one systematic study has
assessed the association between AcMPAG plasma
concentration and the incidence of diarrhea in patients on MMF [17]. We added AcMPAG-d3 stableisotopeelabeled internal standards as done in some
clinical laboratories to monitor the presence of
AcMPAG and provide more extensive results than
just quantiﬁcation of MPA and MPAG. Two concentrations of spiked control samples were used to
monitor the stability of MPA and MPAG. Our data
show that MPA and MPAG are stable for over 6
months when stored at 70  C.The assay requires
only 10 mL of plasma and uses a simple protein
precipitation protocol. We observed that MPA,
MPAG, and AcMPAG eluted at 2.71, 1.94, and
2.18 min, respectively, for a total run time of 6 min.
Our protocol uses an automatic sample-extraction
method (on-line SPE) coupled with an analytical
column to isolate MPA, MPAG, and an added
AcMPAG internal standard from the same sample.
The advantages of our method include a lower
sample volume, automatic extraction procedure,
minimal ion suppression, and good performance.
The method was veriﬁed according to the clinical
laboratory guidelines: Clinical and Laboratory
Standards Institute (CLSI) guideline C62-A Liquid
Chromatography e Mass Spectrometry Methods;
Approved guideline [14]. The veriﬁcation data
demonstrate good linearity, low imprecision, and no
carryover or matrix effects. We used commercially
available calibration standards to evaluate the accuracy of the method. The guideline state that an

Table 3. UPLC-MS/MS within-run and between-run data for each control level.
UPLC-MS/MS Within-run (n ¼ 20)

Analyte

MPA
MPAG

QC
QC
QC
QC

level
level
level
level

1
2
1
2

UPLC-MS/MS Between-run (n ¼ 28)

Mean
(mg/mL)

SD
(mg/mL)

CV (%)

Recovery
(%)

Mean
(mg/mL)

SD
(mg/mL)

CV (%)

Recovery
(%)

2.1
4.9
40.6
118

0.1
0.2
0.5
1.1

4.8
3.2
1.2
0.9

105
98
101
98

2.1
5.2
41
123.6

0.1
0.3
0.6
3.4

4.8
5.8
1.6
2.8

105
104
103
103
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Fig. 3. Ion suppression proﬁle performed with a post-column ﬂow injection of 100 ng/mL MPA and MPAG into the UPLC eluate of drug-free samples
from 10 healthy individuals.

acceptable bias is 15%. The data show a mean bias
of 10% for MPA and 12% for MPAG. These results
suggest that the discrepancy between 6.5% and
13.8% of MPA and between 8% and 14.8% of
MPAG were caused by the use of different standards. The calibrators from Chromsystems were
lyophilized and needed to be reconstituted before
use. The 7-point calibration curve was prepared
from stock liquid standard solutions that are certiﬁed reference materials for determining the accuracy of MPA and MPAG concentrations. Since the
MPA/MPAG concentration is not standardized, we
then used proﬁciency-testing samples to evaluate
the consensus of the MPA results. Using proﬁciency-testing samples from the College of American Pathologists to monitor MPA concentrations,
the bias was <3.5% of the mean value of the peer
group. These samples do not contain MPAG for
evaluation.
In-source fragmentation of MPAG and AcMPAG
was found in our assay and also has been reported
in other studies [18,19]. If MPA is not separated from
MPAG and AcMPAG, the resulting MPA concentrations are affected. In our method, we chromatographically separated MPA, and MPAG, and

AcMPAG to yield baseline resolution of MPA to
more accurately determine the MPA, MPAG, and
AcMPAG concentrations.
PassingeBablock regression analysis showed
good linearity between the immunoassay and our
method. However, the BlandeAltman regression
analysis showed a signiﬁcant positive bias of the
immunoassay in 351 clinical plasma samples. Previous studies have shown that immunoassays may
be affected by the metabolite MPAG or AcMPAG,
overestimating the plasma MPA concentration by
26.25% (95% CI, 21.43e31.07%) [7]. We found that
the mean MPAG/MPA ratio was 31.9 when the
positive bias of the immunoassay was >15.1% and
22.7 when the positive bias was <15.1% (p < 0.05).
These data show that the presence of MPAG affects
quantitation of MPA in the immunoassays.
According to the Tietz Textbook of Clinical
Chemistry and Molecular Diagnostics [20], the
therapeutic range of MPA is 1.0e3.5 mg/mL in patients administered MPA with cyclosporine A and
1.9e4.0 mg/mL in those administered MPA with
tacrolimus. In our analysis MPA levels in 351 renal
transplant patients, a plasma concentration below
the therapeutic range was observed in only 46.7% of

289
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Fig. 4. Comparison of results between UPLC-MS/MS and immunoassay. (A) PassingeBablok regression analysis of immunoassay vs. UPLC-MS/
MS. (B) BlandeAltman plot of immunoassay vs. UPLC-MS/MS.

those co-treated with MPA and tacrolimus and
19.4% of those co-treated with MPA and cyclosporine A.
Studies of MPA pharmacokinetics have shown that
exposure correlates poorly with the dose of the drug,
and many patients on standard ﬁxed dosing have

subtherapeutic concentrations of MPA [21]. Therefore, monitoring plasma concentrations of MPA is
suggested to be useful to compensate for the variable
pharmacokinetic behavior of this drug. According to
the prescribing information, there are no signiﬁcant
sex or age differences in pharmacokinetics. In our
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study, we demonstrated advantages of using the
UPLC-MS/MS platform to quantify MPA and
MPAG. At the same time, we compared this method
to a commercially available immunoassay and evaluated the bias between the two platforms. The UPLCMS/MS platform provided more precise data than
did the immunoassay and could be useful in the
clinical setting.

speciﬁcity for effective monitoring of MPA and its
metabolites in clinical laboratories.

5. Conclusion
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Monitoring plasma concentrations of MPA is
critically important to optimizing patient drug
dosage. UPLC-MS/MS is more accurate than
immunoassay for quantifying plasma MPA. This
veriﬁed method provides greater sensitivity and
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Appendix. Supplementary data

Fig.1. Standard residual and calibration curve for MPA and MPAG. (A) MPA. (B) MPAG.

Table 1. Carryover results for MPA and MPAG. (A) MPA. (B) MPAG.
A
MPA

Concentration
(mg/mL)

L1
L2
L3
H1
H2
L4
H3
H4
L5
L6
L7
L8
H5
H6
L9
H7
H8
L10
H9
H10
L11

1.9
2.4
2.0
11.4
12.6
2.3
11.9
11.9
2.2
2.1
2.0
2.4
11.8
11.8
2.2
13.1
12.3
2.2
12.3
12.1
2.2

Low-Low
Result

High-Low
Result

High Result

2.4
2.0
11.4
12.6
2.3
11.9
11.9
2.2
2.1
2.0
2.4
11.8
11.8
2.2

2.2
12.3
12.1
2.2

Mean
SD

2.2
0.2

High-Low Mean
Low-Low Mean
Carryver
Error Limit

2.2
2.2
0.0
0.6

2.2
0.0

12.1
0.5

High-Low
Result

High Result

B
MPAG

Concentration
(mg/mL)

L1
L2
L3
H1
H2
LA
H3
H4
L5
L6
L7
L8
H5
H6
L9
H7
H8
L10
H9
H10
L11

41.6
41.6
41.1
230.0
235.2
41.4
236.1
240.6
41.5
40.3
40.9
40.3
231.8
237.1
41.2
236.7
234.0
41.0
231.4
233.7
41.7

Low-Low
Result
41.6
41.1

230.0
235.2
41.4
236.1
240.6
41.5
40.3
40.9
40.3
231.8
237.1
41.2
236.7
234.0
41.0
231.4
233.7
41.7

Mean
SD

40.8
0.6

High-Low Mean
Low-Low Mean
Carryver
Error Limit

41.4
40.8
0.5
1.7

41.4
0.3

234.7
3.2
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